Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic

NATCO Pharma Limited announces that Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic Ozempic (Semaglutide). NATCO and Mylan are partnered on the development of generic Ozempic products. The terms of the settlement are confidential.

NATCO's manufacturing partner is Stelis.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 1401.60 as compared to the previous close of Rs. 1354.65. The total number of shares traded during the day was 157517 in over 11517 trades.

The stock hit an intraday high of Rs. 1413.45 and intraday low of 1350.20. The net turnover during the day was Rs. 219270308.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 MylanPharmaceuticals NovoNordisk Settlement USPatentLitigation Ozempic Semaglutide